Synonyms: Ena 713 free base | Exelon®
rivastigmine is an approved drug (FDA (2000), EMA (1998))
Compound class:
Synthetic organic
Comment: Marketed formulations may contain rivastigmine hydrogen tartrate (PubChem CID 14254240).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: rivastigmine |
|
References |
1. Birks J, McGuinness B, Craig D. (2013)
Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev, 5: CD004744. [PMID:23728651] |
2. Henderson EJ, Lord SR, Brodie MA, Gaunt DM, Lawrence AD, Close JCT, Whone AL, Ben-Shlomo Y. (2016)
Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Neurology, Online First. |
3. Luo W, Yu QS, Kulkarni SS, Parrish DA, Holloway HW, Tweedie D, Shafferman A, Lahiri DK, Brossi A, Greig NH. (2006)
Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem, 49 (7): 2174-85. [PMID:16570913] |